Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 1,450,000 shares, a growth of 27.2% from the June 30th total of 1,140,000 shares. Based on an average daily volume of 246,600 shares, the short-interest ratio is currently 5.9 days. Approximately 2.1% of the company’s stock are sold short.
Centessa Pharmaceuticals Stock Up 0.7 %
CNTA stock traded up $0.07 on Tuesday, hitting $10.72. The company had a trading volume of 1,352 shares, compared to its average volume of 306,212. Centessa Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $12.45. The company has a current ratio of 10.37, a quick ratio of 10.37 and a debt-to-equity ratio of 0.36. The stock’s 50-day simple moving average is $9.14 and its 200 day simple moving average is $9.61.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.03. On average, research analysts expect that Centessa Pharmaceuticals will post -1.62 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Report on Centessa Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. HighMark Wealth Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 2nd quarter worth $840,000. Lynx1 Capital Management LP purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $197,000. Farallon Capital Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $4,192,000. Artal Group S.A. boosted its stake in shares of Centessa Pharmaceuticals by 39.5% during the 1st quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after acquiring an additional 400,000 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $33,923,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.
Centessa Pharmaceuticals Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Read More
- Five stocks we like better than Centessa Pharmaceuticals
- Best Aerospace Stocks Investing
- Why SoFi Stock is an Unmissable Growth Opportunity
- How to Capture the Benefits of Dividend Increases
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
- What is the FTSE 100 index?
- Should You Invest in Bonds? Here’s What to Know
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.